24th week of 2011 patent applcation highlights part 56 |
Patent application number | Title | Published |
20110144017 | Protein conjugates and methods for their preparation - Reductive amination of peptide-derived aldehydes with anilines or heteroarylamines containing a property-modifying group provides new, hydrolytically stable protein conjugates, suitable for therapy. | 2011-06-16 |
20110144018 | AGENT FOR PROPHYLAXIS OF REFLEX SYMPATHETIC DYSTROPHY AFTER CEREBRAL APOPLEXY - The present invention is intended to provide a novel pharmaceutical agent having an excellent preventive effect on post-stroke RSD. The present invention provides an agent for preventing the onset of post-stroke RSD, comprising natural calcitonin or a calcitonin derivative as an active ingredient. The present invention is also intended to provide a method for preventing the onset of post-stroke RSD, comprising administering natural calcitonin or a calcitonin derivative and use of natural calcitonin or a calcitonin derivative for producing an agent for preventing the onset of post-stroke RSD. | 2011-06-16 |
20110144019 | METHOD OF TREATING CHRONIC HEART FAILURE - The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin. | 2011-06-16 |
20110144020 | TREATMENT OF INFECTIONS AND OTHER DISORDERS - Microbial infections including anthrax infection, and gastrointestinal disorders, are treated or prevented by administration of an actin-sequestering peptide including amino acid sequence LKKTET, such as Thymosin β4, an isoform of Thymosin β4, oxidized Thymosin β4, or Tβ4 sulfoxide. | 2011-06-16 |
20110144021 | THERAPEUTIC PROTEINS FROM LATEX - The invention refers to compositions that comprise the protein preparation, obtained from the latex of | 2011-06-16 |
20110144022 | Anti-Angiogenic Peptide - The invention relates to an anti-angiogenic peptide corresponding to a fragment of angiostatin molecule, pharmaceutical compositions containing it and the use thereof in the preventive or therapeutic treatment of diseases involving angiogenesis. | 2011-06-16 |
20110144023 | Nano Cancer Barrier Device (NCBD) to Immobilize and Inhibit the Division of Metastic Cancer Stem Cells - The present invention provides methods, compositions, and kits wherein nanomaterials are used for inhibiting cancer stem cell division, colony formation, spheroid formation and self-renewal. The present invention also provides methods, compositions, and kits wherein nanomaterials are used for treating cancer, coating tumors, and inhibiting metastasis. The present invention also provides methods, compositions, and kits wherein nanomaterials are used for inducing cells to go into stasis. The present invention further provides methods for isolating tumors, inhibiting bleeding, and marking margins of tumors and organs during surgery with a nanomaterial. | 2011-06-16 |
20110144024 | PREVENTION AND TREATMENT OF RADIATION INJURY - The invention relates to the field of radiation injury. More particularly, this invention relates to the protection against/prevention of and treatment of diseases caused by ionizing radiation by the use of thrombomodulin. | 2011-06-16 |
20110144025 | Methods of Reducing Hemorrhage Due to Surgical Procedure - The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose. | 2011-06-16 |
20110144026 | Method of Treating Low Blood Pressure - A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient. | 2011-06-16 |
20110144027 | PHARMACEUTICAL COMPOSITIONS FOR PROMOTING WOUND HEALING - The present invention relates to pharmaceutical compositions and methods for promoting wound healing. The invention also relates to methods of making pharmaceutical compositions disclosed herein. Pharmaceutical compositions are disclosed comprising an effective amount of a 2-alkoxyadenosine or 2-aralkoxyadenosine, about 10% to about 70% w/w propylene glycol and a thickening agent. | 2011-06-16 |
20110144028 | MODULATING CELLULAR ELECTROPHYSIOLOGY - The present invention relates to compositions, apparatus, and methods for improving the viability of cells, including, but not limited to, nonexcitable cells, and tissues expressing exogenous polynucleotides that encode membrane proteins that regulate that flow of ions across the cell membrane. The viability of the cells and tissues may be improved by contacting the cells or tissue with one or more ion channel blocking agents. Membrane proteins that regulate the flow of ions across the cell membrane include, but are not limited to, ion channels. | 2011-06-16 |
20110144029 | Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases - The present invention provides models for studying the development of, and/or pathologies associated with neurodegenerative diseases, and agents that can modulate such development and/or pathologies. | 2011-06-16 |
20110144030 | CONJUGATE OF HYALURONIC ACID FOR COSMETIC TREATMENT AND PREPARATION METHOD - This invention discloses a new conjugate compound that comprises at least one HA oligomer derivatised through one thiolated linker, whereby it binds to at least one metal nanoparticle, such as, for example, a gold nanoparticle. Moreover, it discloses methods of obtaining it, as well as the use thereof in a cosmetic treatment, and cosmetic compositions that contain them. | 2011-06-16 |
20110144031 | Pharmaceutical composition for inducing damages of endothelial cells and treating tumor and method for treating tumor by using the same - The present invention relates to a pharmaceutical composition for inducing damages of endothelial cells, a pharmaceutical composition for treating a tumor, and a method for treating a tumor by using the same. In addition, the pharmaceutical compositions for inducing damages of endothelial cells comprises: an effective amount of Concanavalin A (Con A). | 2011-06-16 |
20110144032 | BIOLOGICAL APPLICATIONS OF STEROID BINDING DOMAINS - A polypeptide comprising an androgen binding region, the androgen binding region capable of binding to an androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available androgen is decreased. | 2011-06-16 |
20110144033 | Proteasome Inhibitors and Methods of Using the Same - The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity. | 2011-06-16 |
20110144034 | INHIBITION OF TUMOR METASTASES USING PROTEIN KINASE C (PKC) INHIBITORS - Described are methods for reducing tumor metastasis in an animal by administering an inhibitor of a protein kinase C (PKC) isozyme. | 2011-06-16 |
20110144035 | Methods and Compositions for Treating Conditions of the Eye - Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature. | 2011-06-16 |
20110144036 | HIP/PAP Polypeptide Composition for Use in Liver Regeneration and for the Prevention of Liver Failure - This invention is based on the experimental finding that HIP/PAP has mitogenic and antiapoptotic effects in vitro on hepatocytes in primary culture. Moreover, HIP/PAP is a mitogenic and anti-apoptotic molecule for hepatocytcs, in vivo, during liver failure and liver regeneration. The present invention is also based on the experimental finding that HIP/PAP administration has no adverse effects in mammals. This invention concerns a pharmaceutical composition for stimulating liver regeneration in vivo including after chronic/acute liver failure, comprising an effective amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue (36) and ending at the amino acid residue (175) of sequence SEQ ID No 1, in combination with at least one physiologically acceptable excipient. | 2011-06-16 |
20110144037 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use - The presently disclosed and claimed inventive concepts include inhibitors of antiplasmin cleaving enzyme (APCE) and fibroblast activation protein alpha (FAP) which can be used in various therapies related to disorders of fibrin and α | 2011-06-16 |
20110144038 | HUMAN CD154-BINDING SYNTHETIC PEPTIDE AND USES THEREOF - The invention refers to a synthetic peptide comprising an amino acid sequence of seven residues in length, preferably flanked by 2 cysteine residues at both ends, which is capable of specifically recognizing human CD154 and blocking CD40:CD154 interaction, thereby inhibiting the biological effects depending on such interaction. The peptide of the invention, which is preferably in a cyclic form, is suitable for use for diagnostic and therapeutic applications, especially for the diagnosis and therapy of tumor, inflammatory diseases and transplant rejection. | 2011-06-16 |
20110144039 | ANTIOXIDATIVE AND HEPATOPROTECTIVE COMPOSITIONS CONTAINING DIARYHEPTANOIDS FROM ALNUS JAPONICA - The present invention relates to antioxidative and hepatoprotective compositions, and more particularly to antioxidative and hepatoprotective compositions comprising diarylheptanoid compounds from | 2011-06-16 |
20110144040 | Acteoside and acteoside-rich plant extracts for increasing athletic performance in humans - The present invention relates to increasing the athletic performance of humans using acteoside. This may be in the form of a pure compound, or plant extracts containing at least 10% acteoside by weight. Application of this invention provides increased strength, muscle power, endurance, muscle protein content, and reduced fatigue. | 2011-06-16 |
20110144041 | Methods for Treating Inflammatory Bowel Disease - A method is described for treating inflammatory bowel disease in a subject in need thereof. The method comprises administering a formulation comprising at least one ganglioside to the subject, wherein the formulation comprises at least about 50% GD3 by weight of total ganglioside content. | 2011-06-16 |
20110144042 | Novel Polysaccharides with Antithrombotic Activity Comprising at Least One Covalent Bond with Biotin or a Biotin Derivative - The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing avidin or streptavidin which makes it possible to neutralize these polysaccharides. | 2011-06-16 |
20110144043 | Stat modulators - The present invention is directed to methods, kits and compositions for modulating the activity of Stat molecules (e.g., Stat1, Stat3 and Stat5). The compounds of the invention are useful for treating and/or preventing disorders characterized by Stat dysregulation, such as hyperproliferative disorders. Further, the compounds of the present invention are also useful in culturing stem cells and treating ischemic disorders. | 2011-06-16 |
20110144044 | Composition and method for increasing post workout recovery - The composition of a dietary supplement is provided for increasing post workout recovery, increasing replenishment and regaining energy following exercise. A method for achieving the same is also provided. The present composition comprises branched chain amino acids, caffeine and a source of carbohydrates including waxy maize. The dietary supplement may further comprise one or more of Ginseng providing ginsenoside saponins, and Fenugreek seeds providing 4-Hydroxyisoleucine. | 2011-06-16 |
20110144045 | USE OF FUMAGILLIN AND THE DERIVATIVES THEREOF TO INCREASE THE BIOAVAILABILITY OF THE MACROCYCLIC LACTONES - A method for increasing the bioavailability of antiparasitic active ingredients, and therefore to potentiate the effects thereof, including combining antiparasitic active ingredients with an adjuvant, wherein, the antiparasitic active ingredients are capable of being recognized and binding to cellular transporters in order to be transported out of cells without being able to reach an intracellular therapeutic target, the transporters being present in the cells of the human or animal organism to which the antiparasitic active ingredients are administered, and, optionally, in the cells of parasites against which the antiparasitic active ingredients are administered, the adjuvant is a compound corresponding to fumagillin of the following formula (II): | 2011-06-16 |
20110144046 | ANTHELMINTIC COMPOSITIONS - An anthelmintic composition comprising two or more active agents, each agent being selected from a separate anthelmintically active family, the families being a macrocyclic lactone (ML), levamisole or its equivalent and a benzimidazole, in a suitable carrier, which includes at least one effective protective agent, which stabilises the chemical and physical activity of the ML, such as hydroxypropyl starch phosphate. | 2011-06-16 |
20110144047 | COMBINED METHOD FOR PREDICTING THE RESPONSE TO AN ANTI-CANCER THERAPY - The invention provides methods for predicting the response to a topoisomerase Ilα inhibitor therapy in an individual having cancer, wherein the methods comprise the steps of determining TIMP-I DNA aberration/TIMP-1 protein aberration in combination with determining DNA aberration in TOP2A/HER2 amplicon on chromosome 17q21 including TOP2A and HER2 or aberrations of TOP2A and ErbB2 protein expression. Further provided are methods of treating cancer by using said topoisomerase Ilα inhibitor therapy. The invention also comprises a kit for the application of the methods for predicting the response to a topoisomerase Ilα inhibitor therapy in an individual having cancer. | 2011-06-16 |
20110144048 | Novel Uses of Neuraminidase Inhibitors in Infectious Diseasess - The present invention relates to methods of decreasing the infectivity, morbidity and rate of mortality, in treating diseases associated with a variety of pathogenic organisms, specifically diseases involving one or more pathogens that require neuraminidase as a virulence factor. In addition, the present invention uses biology based therapy to treat neuraminidase dependent infections or diseases dependent on sialic acid metabolism. | 2011-06-16 |
20110144049 | Treating Cardiac Arrhythmias, Heart Failure, Peripheral Artery Disease and Stroke with Cyclopentyl-Triazolo-Pyrimidine or Derivative Thereof - The present invention relates to new methods for treating and/or preventing cardiac arrhythmias, heart failure, stroke and/or peripheral artery disease by administering a composition comprising triazolopyrimidine, or derivative or metabolite thereof. In particular, the present invention relates to methods for treating cardiac arrhythmias, heart failure, stroke and/or peripheral artery disease by administering CycloPentyl-TriazoloPyrimidine. | 2011-06-16 |
20110144050 | SALTS OF HIV INHIBITOR COMPOUNDS - The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to processes and intermediates useful for preparing such salts. | 2011-06-16 |
20110144051 | Compositions and methods for treatment of mitochondrial diseases - Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidien nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies. | 2011-06-16 |
20110144052 | NIACIN PRODRUGS AND DEUTERATED VERSIONS THEREOF - The invention relates to prodrugs of niacin and their use in pharmaceutical composition and therapeutic treatment of disease. | 2011-06-16 |
20110144053 | Process for Obtaining Purified Pterostilbene and Methods of Use Thereof - The present invention relates to a process of extraction and purification of a stilbenoid, pterostilbene, from botanical sources. The process involves obtaining pterostilbene having high degree of purity and the present invention also relates to pure form of pterostilbene obtained. The invention also relates to complexing the pterostilbene with carriers such as cyclodextrin for improving its water solubility and bioavailability. The present invention also describes a process for inhibition of Histone Deacetylases using pterostilbene optionally along with a carrier, and a method of managing Poly Glutamine repeat disorders by the administration of pterostilbene optionally along with a carrier. | 2011-06-16 |
20110144054 | Polyol and Polyether Iron Oxide Complexes as Pharmacological and/or MRI Contrast Agents - Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL/sec to less than 1 mL/min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo. | 2011-06-16 |
20110144055 | Health Care - The use of a pharmaceutical regimen to deter in an individual, as the individual ages, the development of a cardiovascular disease (CVD) or Alzheimer's disease or to treat an individual who has CVD or Alzheimer's, the individual ingesting on a daily basis a regimen comprising pharmaceutically effective amounts of magnesium salicylate and naproxen, the amount of the magnesium salicylate being no greater than about 260 mg, and also the use of a pharmaceutical regimen to treat an individual who has Type 2 diabetes, the regimen being ingested daily by the individual and comprising pharmaceutically effective amounts of at least one glucose-lowering drug and magnesium salicylate in an amount no greater than about 260 mg. | 2011-06-16 |
20110144056 | PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH - The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease | 2011-06-16 |
20110144057 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF - The present invention is directed to compounds of formula (I) | 2011-06-16 |
20110144058 | INSECTICIDAL COMPOSITIONS - The present invention relates to insecticidal mixtures of chloronicotinyl insecticides of the formula (I) | 2011-06-16 |
20110144059 | PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES - The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications. | 2011-06-16 |
20110144060 | SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS - The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I | 2011-06-16 |
20110144061 | NANOPARTICLE/DISPERSANT COMPLEX, NANOPARTICLE DISPERSION LIQUID, AND NANOPARTICLE/MATRIX-MATERIAL COMPLEX - Provided are a nanoparticle/dispersant complex having excellent dispersibility and long-term stability in a dispersion medium, a production method therefor, and a nanoparticle dispersion liquid and a nanoparticle/matrix-material complex which are colorless and transparent even at high concentrations. In the nanoparticle/dispersant complex, a nanoparticle is covered with a dispersant containing a heterocyclic cationic group and one of an oxo acid group containing a sulfur atom or a phosphorus atom and an anion moiety of the oxo acid group; in the nanoparticle dispersion liquid, the nanoparticle/dispersant complex is dispersed into a dispersion medium; in the nanoparticle/matrix-material complex, the nanoparticle/dispersant complex is dispersed into a matrix material; and the production method for a nanoparticle/dispersant complex comprises forming, under a presence of the dispersant, a nanoparticle covered with the dispersant from a nanoparticle precursor. | 2011-06-16 |
20110144062 | DERMATOLOGICAL ANTI-WRINKLE AGENT - A dermatological anti-wrinkle agent and an anti-wrinkle cosmetic are stable and satisfactorily effective against wrinkles. The dermatological anti-wrinkle agent includes a tocopherol phosphate represented by the following formula (1): | 2011-06-16 |
20110144063 | GLYCEROPHOSPHOLIPIDS FOR THE IMPROVEMENT OF COGNITIVE FUNCTIONS - The invention described herein provides a preparation comprising a non-mammalian derived mixture of serine glycerophospholipid conjugates with a specific content and specific conjugation patterns of LA, linolenic acid (alpha-linolenic acid, gamma-linolenic acid) DHA and EPA which depend on utilizing different sources of lipids, and uses of such preparations. | 2011-06-16 |
20110144064 | Inhibitors of Kynurenine Aminotransferase and Uses Therefor - Provided herein are methods of decreasing a level of kynurenic acid in a cell and of treating a pathophysiological condition in a subject associated with an increase in kynurenic acid in a subject. In these methods the inhibitory action of dicarboxylic acids or derivatives or analogs thereof are effective to inhibit activity of kynurenine aminotransferase II. Also provided is a method of screening for potential inhibitory compounds for kynurenine aminotransferase II. The dicarboxylic acids or derivatives or analogs thereof may have the structural formula, where R | 2011-06-16 |
20110144065 | SELECTIVE HIGH-AFFINITY POLYDENTATE LIGANDS AND METHODS OF MAKING SUCH - This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity. | 2011-06-16 |
20110144066 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME - Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein. | 2011-06-16 |
20110144067 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives - The invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or pharmaceutical compositions for treating, preventing, or delaying the onset and/or develop of a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy. | 2011-06-16 |
20110144068 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS - 3,4-diarylpyrazole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. | 2011-06-16 |
20110144069 | COMPOUNDS FOR TREATING VIRAL INFECTIONS - The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection. | 2011-06-16 |
20110144070 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme. | 2011-06-16 |
20110144071 | CRYSTALLINE ACTIVE INGREDIENT MICROPARTICLES, METHOD FOR PRODUCING THE SAME AND USE THEREOF IN DRUGS - A method for producing highly crystalline and stable microparticles of an active substance with a very narrow size distribution. The microparticles being crystallized out of a suspension made of primary particles of the active substance, a solution of the active substance, a non-solvent for the active substance and inert formed pieces. The resulting microparticles hare highly stable largely independent of the physiochemical properties of the active substance and can be especially suitable for fast release dosage forms of pharmaceuticals. | 2011-06-16 |
20110144072 | Antiglucocorticoid Therapy for the Prevention of Neurological Damage in Premature Infants - This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for preventing neurological damage associated with glucocorticoid therapy in ventilator-dependent low birth weight preterm infants. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. | 2011-06-16 |
20110144073 | GLUCOCORTICOIDS ATTACHED TO NITRATE ESTERS VIA AN AROMATIC LINKER IN POSITION 21 AND THEIR USE IN OPHTHALMOLOGY - The invention relates to nitrooxy derivatives of fluocinolone acetonide, triamcinolone acetonide, betamethasone and beclomethasone, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for treating diabetic macular edema, diabetic retinopathy, macular degeneration, age-related macular degeneration and other diseases of retina and macula lutea. | 2011-06-16 |
20110144074 | CASPASE INHIBITORS AND USES THEREOF - This invention provides caspase inhibitors of formula I: | 2011-06-16 |
20110144075 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme. | 2011-06-16 |
20110144076 | PRETERM DELIVERY DIAGNOSTIC ASSAY - The present invention in one aspect relates generally to the identification, provision and use of a plurality of biomarkers to provide risk assessment of a woman for preterm delivery, and products and processes related thereto. In one aspect, a novel plurality of biomarkers as described herein is provided to determine a risk for preterm delivery. In one aspect are methods for determining a risk of preterm delivery in a subject. In another aspect are methods of predicting the likelihood of preterm delivery in a subject. In yet another aspect are methods for identifying subjects at risk of preterm delivery, and kits for use in the method In yet another aspect are nucleic acid arrays comprising nucleic acid probes that hybridize to preterm delivery marker genes. | 2011-06-16 |
20110144077 | TREATMENT OF RETINAL DEGENERATION - The use of a compound having a gon-4-ene nucleus, said nucleus having attached thereto, in the 13 position, a polycarbon-alkyl radical having 2 to about 16 carbon atoms, said compound containing at least 19 and up to 40 carbon atoms in its carbon-carbon skeleton, in the manufacture of a medicament for the treatment or prevention of a disease or condition characterised by apoptosis or degeneration of mammalian cells. | 2011-06-16 |
20110144078 | TRANSITION METAL COMPLEXES OF CORROLES FOR PREVENTING CARDIOVASCULAR DISEASES OR DISORDERS - Transition metal complexes of amphiphilic/bipolar corroles, optically active isomers or pharmaceutically acceptable salts thereof are useful for prevention of a cardiovascular disease or disorder in a subject susceptible to develop such a cardiovascular disease or disorder. | 2011-06-16 |
20110144079 | ANTIMICROBIAL SYSTEM - The present invention relates to the use of ionic liquids as antimicrobial agents, and to the use of antimicrobial compositions comprising an ionic liquid, a film-enhancing composition and a viscosity controlling agent. The invention further relates to methods of disinfecting substrate surfaces, to substrates produced by such methods, and to novel ionic liquid compositions. | 2011-06-16 |
20110144080 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS - The invention provides compounds of the formula: (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R | 2011-06-16 |
20110144081 | PYRROLIDINE DERIVATIVES - The present invention relates to compounds of formula | 2011-06-16 |
20110144082 | COMPOUNDS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES - A compound of formula A1 or A2 for use in the treatment of a demyelinating peripheral neuropathy: | 2011-06-16 |
20110144083 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions - The present invention relates to substituted xanthines of general formula | 2011-06-16 |
20110144084 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS - The present invention is directed to compounds of formula (I), | 2011-06-16 |
20110144085 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS - Compounds of Formula (I), in which A, B, R | 2011-06-16 |
20110144086 | INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS - Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, Formula (I) or a pharmaceutically acceptable salt thereof, wherein R | 2011-06-16 |
20110144087 | SHORT ACTING BENZOTHIAZEPINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF - The present invention relates to short-acting calcium channel blocking compounds and their use to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension in general, hypertension been.) fore, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods. | 2011-06-16 |
20110144088 | METHOD OF TREATING SLEEP DISORDERS - A method of treating at least one symptom or condition associated with but not limited to: Sleep Disorders including but not limited to 1) Dyssomnia Disorders including but not limited to: a) Primary inomnia, b) Primary Hypersomnia, and c) narcolepsy; and 2) Parasomnias Disorders including but not limited to a) Nightmare Disorder, Sleep Terror Disorder and Sleepwalking Disorder, comprising administering an effective amount of Formula I | 2011-06-16 |
20110144089 | METHOD OF TREATING SCHIZOPHRENIA AND OTHER DISORDERS - A method of treating at least one symptom or condition associated with but not limited to: 1) Schizophrenia and other Psychotic Disorders including but not limited to Psychotic Disorder, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, and Psychotic Disorder Due to a General Medical Condition and 2) Dementia and other Cognitive Disorders comprising administering an effective amount of Formula I | 2011-06-16 |
20110144090 | COMPOUNDS AND METHODS OF USE THEREOF - Indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds. | 2011-06-16 |
20110144091 | Inhibitors of Diacylglycerol Acyltransferase - This invention provides compounds of formula I: | 2011-06-16 |
20110144092 | SUBSTITUTED ALKYL PYRIMIDIN-4-ONE DERIVATIVES - A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 2011-06-16 |
20110144093 | METHOD OF TREATING ORGANOPHOSPHOROUS POISONING - A method for treating organophosphorous poisoning (OP) comprising administering to a mammal at risk for OP poisoning an OP poisoning-inhibiting amount of galantamine. | 2011-06-16 |
20110144094 | HETEROCYCLIC TETRACYCLIC TETRAHYDROFURAN DERIVATIVES - This invention concerns novel substituted heterocyclic tetracyclic tetrahydrofuran derivatives with binding affinities towards serotonin receptors, in particular 5-HT | 2011-06-16 |
20110144095 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions - The present invention relates to substituted xanthines of general formula | 2011-06-16 |
20110144096 | TREATING VARIOUS DISORDERS USING TRKB AGONISTS - Novel compounds and methods for activating the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted C | 2011-06-16 |
20110144097 | 2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-PHENYL]-AMIDES - The present invention relates to 2-Amino-5,5-difluoro-5,6-dihydro-4H-[1,3]oxazin-4-yl)-phenyl]-amides of formula I | 2011-06-16 |
20110144098 | AMINO OXAZINE DERIVATIVES - This invention relates to 5,6-dihydro-4H-[1,3]oxazin-2-ylamine compounds of the formula | 2011-06-16 |
20110144099 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES - Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed. | 2011-06-16 |
20110144100 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS - Compounds of Formula (I): I in which B, R | 2011-06-16 |
20110144101 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS - The present invention provides methods for the use of compounds having formula (I) in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R | 2011-06-16 |
20110144102 | CALCIMIMETIC COMPOUND FOR USE IN THE TREATMENT OF EPITHELIAL INJURY - This invention relates generally to the field of medicine and, more specifically, to methods for treating epithelial injury, in particular, due to ischemia, hypoxia, trauma, chemolytics or radiation exposure. | 2011-06-16 |
20110144103 | PYRROLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - The present invention relates to substituted pyrrole compounds and compositions comprising substituted pyrrole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted pyrrole compound of the invention, or a pharmaceutical composition comprising such a compound. | 2011-06-16 |
20110144104 | PYRROLIDINYL-ALKYL-AMIDE DERIVATIVES, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATION AS CCR3 RECEPTOR LIGANDS - The present invention relates to pyrrolidinyl-alkyl-amide derivatives of formula (I) or (IA) | 2011-06-16 |
20110144105 | AZAINDOLE GLUCOKINASE ACTIVATORS - Provided herein are compounds of the formula (I): | 2011-06-16 |
20110144106 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES - The present invention relates to a compound of formula (I) | 2011-06-16 |
20110144107 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA - The invention provides a class of compounds of formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria. | 2011-06-16 |
20110144108 | SUBSTITUTED PIPERIDINE COMPOUNDS AND METHODS OF THEIR USE - Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors. | 2011-06-16 |
20110144109 | Derivatives of 1--4-methylpiperazine, synthesis process and uses thereof - The present invention concerns pyrrole compounds, derivatives of 1-{[1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl]methyl}-4-methylpiperazine (BM212). The invention concerns the use of the described compounds as antitubercular agents having high activity and low toxicity and process to obtain intermediates and final compounds. | 2011-06-16 |
20110144110 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents - The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. | 2011-06-16 |
20110144111 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH BETA-AMYLOID ACCUMULATION CONTAINING MORPHOLIN OR PIPERAZINE BASED COMPOUNDS HAVING SO3H OR COOH AS ACTIVE INGREDIENT - Disclosed herein is a method for treating diseases associated with beta amyloid accumulation, including administering to a patient a therapeutically effective amount of morpholine or piperazine based compounds including a sulfuric or carboxylic acid structure represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof: | 2011-06-16 |
20110144112 | APOPTOSIS PROMOTERS - Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member. | 2011-06-16 |
20110144113 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS - The present invention is directed to [1,2,4]triazolo[4,3-b][1,2,4]triazines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. | 2011-06-16 |
20110144114 | SUBSTITUTED TRIAZINONE DERIVATIVES - Triazinone derivatives represented by formula (I) | 2011-06-16 |
20110144115 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The present invention is related to novel substituted 1-benzylcinnolin-4(1H)-one derivatives having affinity for cannabinoid CB | 2011-06-16 |
20110144116 | DERIVATIVES OF (BRIDGED PIPERAZINYL)-1-ALKANONE AND USE THEREOF AS p75 INHIBITORS - The present invention relates to derivatives of ((phenyl)-3,6-dihydropyridin-1-yl)(bridged piperazinyl)-1-alkanone derivatives and ((phenyl)-2,5-dihydropyrrol-1-yl) (bridged piperazinyl)-1-alkanone corresponding to Formula (I): | 2011-06-16 |